Health Canada requires generic medications to demonstrate bioequivalence to the original brand, meaning the body absorbs and uses the active ingredient in the same way
This phase utilizes chemical processes like oxidation, reduction, hydrolysis, hydration, and dehalogenation of fat-soluble toxins
Long-Term Considerations Weight Regain After Discontinuation Both medications are associated with weight regain after discontinuation: STEP 1 extension data showed that participants who stopped semaglutide regained approximately two-thirds of their lost weight over the following year (Wilding et al., Diabetes, Obesity and Metabolism , 2022) Long-term data for tesofensine is more limited, but weight regain is expected given that the appetite-suppressing mechanism ceases when the medication is stopped This underscores the importance of viewing these medications as long-term or indefinite treatments for chronic obesity management, rather than short-term interventions
Ozempic has been shown to: Reduce HbA1c (a measure of long-term blood glucose control) by 11.5% on average, with variations depending on baseline levels and dose Improve insulin sensitivity, primarily as a consequence of weight reduction Reduce visceral adiposity (fat around internal organs) as part of overall weight loss, which is particularly beneficial for cardiovascular health Lower blood pressure modestly in many patients Improve lipid profiles, including reductions in triglycerides It is important to note that weight loss is not universalsome patients experience minimal weight change whilst still achieving improved glycaemic control
